Navigation Links
LA BioMed's Dr. Patricia Dickson researching treatments for neurodegenerative disorders

LOS ANGELES (May 30, 2012) Patricia Dickson, M.D., principal investigator at The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), is co-principal investigator of a project that was just awarded a $5.5 million grant from the California Institute for Regenerative Medicine (CIRM). The goal of the project is to develop a stem cell based therapy for the treatment of mucopolysaccharidosis I (MPS I), a fatal pediatric lysosomal storage disease that causes neurodegeneration as well as defects in other major organ systems. Dr. Dickson is working with lead investigator Philip H. Schwartz, Ph.D., senior scientist at the CHOC Children's Research Institute and managing director of the facility's National Human Neural Stem Cell Resource.

For nearly a decade, Dr. Dickson's research at LA BioMed has focused on enzyme replacement therapy for mucopolysaccharidosis, a group of metabolic disorders caused by the absence or malfunctioning of enzymes needed to break down molecules - called glycosaminoglycans - which help build bone, cartilage, connective tissue and other essential parts of the body. As part of this study, she and her colleagues will begin with proof-of-principle experiments for MPS I.

"Dr. Dickson has been at the forefront of mucopolysaccharidosis research for many years, working tirelessly to help develop therapies for MPS I," said David I. Meyer, Ph.D., president and CEO of LA BioMed. "We congratulate her on her continued success, and for her role in this project which could be an important breakthrough for children suffering from neurodegenerative disorders."

"The unique aspect of this research is that it uses a single donor for the transplantation of stem cells into the body and the brain, which allows the best treatment for both physical and neurological disease and avoids rejection of neural stem cell grafts by the host immune system," said Dr. Dickson. "Pediatric neurodegenerative diseases are generally neglected in stem cell research, but stand the greatest chance of success. The high probability of success, along with the need to alleviate suffering in children, is why we believe the first applications of stem cell therapies should be for these kids."

Dr. Schwartz, Dr. Dickson and project collaborators are working to address two critical issues in the development of a therapeutic candidate based on stem cells: that early intervention is not only required but is indeed possible in this patient population, and that the concept of immune tolerance is also required, where the immune system is trained to attack only real threats in the body but not the body's own cells or tissues.

To date, there is still a significant unmet medical need to better impact and prevent the neurodegenerative processes in this disease. If successful in MPS I, this technique can be expanded to help treat other neurodegenerative disorders due to lysosomal storage.


Contact: Diana Soltesz
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)

Related medicine news :

1. Sodexo Names Patricia Bellinger to North America Advisory Board
2. What Causes A Person To Be Mentally Ill? Author Who Has Spent Decades Researching Topic Says He Has the Answer
3. Global Basecamps Launches New Website: Researching and Booking Sustainable Travel Has Never Been Easier
4. Neuroimaging study may pave way for effective Alzheimers treatments
5. Charging less for more effective treatments could reduce health care costs while improving health
6. NIH grants to Childrens Hospital will advance novel stem cell treatments for blood disorders
7. Roseville Radiation Oncology Center (ROC) Redefines Efficiency With Elekta VMAT Radiotherapy Treatments
8. Two Sepsis Treatments Look Equally Effective
9. Heart Stem Cells Move Closer to Human Treatments
10. New Ankle Arthritis Treatments Help Boomers Stay Active
11. Larynx preservation treatments result in low instance of severe voice disability, nutritional dysfunction
Post Your Comments:
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
Breaking Medicine Technology: